ID: ALA229212

Max Phase: Preclinical

Molecular Formula: C22H26F3N5O2

Molecular Weight: 449.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)CCNC(=O)c1ccc(N2CCN(C(=O)c3ccccc3C(F)(F)F)CC2)nn1

Standard InChI:  InChI=1S/C22H26F3N5O2/c1-15(2)9-10-26-20(31)18-7-8-19(28-27-18)29-11-13-30(14-12-29)21(32)16-5-3-4-6-17(16)22(23,24)25/h3-8,15H,9-14H2,1-2H3,(H,26,31)

Standard InChI Key:  NGGBGFKKADSXPM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 449.48

Molecular Weight (Monoisotopic): 449.2039

AlogP: 3.23

#Rotatable Bonds: 6

Polar Surface Area: 78.43

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 1.61

CX LogP: 3.36

CX LogD: 3.36

Aromatic Rings: 2

Heavy Atoms: 32

QED Weighted: 0.73

Np Likeness Score: -1.88

References

1. Liu G, Lynch JK, Freeman J, Liu B, Xin Z, Zhao H, Serby MD, Kym PR, Suhar TS, Smith HT, Cao N, Yang R, Janis RS, Krauser JA, Cepa SP, Beno DW, Sham HL, Collins CA, Surowy TK, Camp HS..  (2007)  Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.,  50  (13): [PMID:17530838] [10.1021/jm070219p]

2. Zhang Z, Sun S, Kodumuru V, Hou D, Liu S, Chakka N, Sviridov S, Chowdhury S, McLaren DG, Ratkay LG, Khakh K, Cheng X, Gschwend HW, Kamboj R, Fu J, Winther MD..  (2013)  Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.,  56  (2): [PMID:23245208] [10.1021/jm301661h]

Source

Source(1):

• Scientific Literature